Cocrystal Pharma, Inc.
COCP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001412486
No open-market purchases or sales by Cocrystal Pharma, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $1.17M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $19.8M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +1 vs. previous quarter
- 27
- 13F valueReported value at the end of Q2 2026
- $1.17M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$8.83M
- No comparable prior period
- Free cash flow, FY2025
- -$8.20M
- No comparable prior period
- Revenue, Q2 FY2026
- $105.0K
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 179.2K
- Shares sold short
- Change
- +3.95K
- +2.3% vs. previous
- Days to cover
- 4.89
- At average daily volume
Superinvestors holding COCP, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding COCP at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Cocrystal Pharma, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 6, 2026 (view filing)5:11 PM ET | Aug 5 | 1 day | Frost Phillip MD Et AlDirector, 10% Owner | PPurchase | +10.0K | $0.9816 | +$9.82K | +0.5%1.99M after | |
| Aug 5, 2026 (view filing)4:10 PM ET | Aug 3 | 2 days | Frost Phillip MD Et AlDirector, 10% Owner | PPurchase | +75.0K | $0.9412 | +$70.6K | +3.9%1.98M after | |
| Feb 25, 2026 (view filing) | Feb 24 | 1 day | Frost Phillip MD Et AlDirector, 10% Owner | PPurchase | +20.0K | $1.00 | +$20.0K | +1.1%1.91M after | |
| Feb 9, 2026 (view filing) | Feb 6 | 3 days | Frost Phillip MD Et AlDirector, 10% Owner | PPurchase | +50.0K | $0.95 | +$47.5K | +2.7%1.89M after | |
| Jan 2, 2026 (view filing) | Dec 31, 2025 | 2 days | Frost Phillip MD Et AlDirector, 10% Owner | PPurchase | +50.0K | $0.95 | +$47.5K | +2.8%1.84M after | |
| Dec 31, 2025 (view filing) | Dec 30 | 1 day | Frost Phillip MD Et AlDirector, 10% Owner | PPurchase | +20.0K | $0.97 | +$19.4K | +1.1%1.79M after | |
| Dec 29, 2025 (view filing) | Dec 24-26 | 5 days | Frost Phillip MD Et AlDirector, 10% Owner | PPurchase | +65.0K | $0.97 | +$63.0K | +3.8%1.77M after | 2 lots |
| Nov 28, 2025 (view filing) | Nov 26 | 2 days | Frost Phillip MD Et AlDirector, 10% Owner | PPurchase | +4.00K | $0.9938 | +$3.98K | +0.2%1.70M after | 2 lots |
| Nov 25, 2025 (view filing) | Nov 25 | Same day | Frost Phillip MD Et AlDirector, 10% Owner | PPurchase | +20.0K | $0.94 | +$18.8K | +1.2%1.70M after | |
| Apr 6, 2023 (view filing)4:01 PM ET | Apr 4 | 2 days | Frost Phillip MD Et Al and 1 otherDirector, 10% Owner | PPurchase | +1.02M | $1.97 | +$2.00M | +333.3%1.32M after |
Top 10 13F holders, Q2 2026
See all 27 holdersThe largest institutional positions in Cocrystal Pharma, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 358,228 | $376.1K | 0.00% | +118,257+49.3% | Added |
| Renaissance Technologies LLC | 179,628 | $188.6K | 0.00% | +55,700+44.9% | Added |
| Two Sigma Investments, LP | 175,379 | $184.1K | 0.00% | +175,379 | New |
| Geode Capital Management, LLC | 76,208 | $80.0K | 0.00% | −14,023−15.5% | Reduced |
| BlackRock, Inc. | 73,746 | $77.4K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 45,118 | $47.4K | 0.00% | +45,118 | New |
| Neuberger Berman Group LLC | 31,886 | $33.5K | 0.00% | 00.0% | Unchanged |
| XTX Topco Ltd | 29,342 | $30.8K | 0.00% | −6,689−18.6% | Reduced |
| Jane Street Group, LLC | 25,761 | $27.0K | 0.00% | +13,050+102.7% | Added |
| Vanguard Fiduciary Trust Co | 24,016 | $25.2K | 0.00% | 00.0% | Unchanged |
Holders of 5% or more of COCP
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Cocrystal Pharma, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Opko Health, Inc. | 13D/A | 29.60%5.69M shares | 0.00 ppfrom 29.60% | Aug 7, 20262 filings | Nov 6, 2026 | SEC |
| Frost Phillip MD Et Al | 13D/A | 13.90%2.78M shares | −3.90 ppfrom 17.80% | Jun 10, 20215 filings | Aug 7, 2026 | SEC |